Journal of Clinical Endocrinology & Metabolism, Vol 81, 4059-4067, Copyright © 1996 by Endocrine Society

ARTICLES

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus

K Cusi, A Consoli and RA DeFronzo
Diabetes Division, University of Texas Health Science Center, San Antonio 78284, USA.

Metformin is a biguanide that has been shown to effectively lower plasma glucose levels in subjects with noninsulin-dependent diabetes mellitus (NIDDM). However, its mechanism of action remains unknown. Studies that have examined the effect of metformin on hepatic glucose production (HGP) and muscle glucose utilization in NIDDM have yielded conflicting results, and little information is available about the action of metformin on lactate turnover and gluconeogenesis from lactate in humans. We studied 20 NIDDM subjects and 8 nondiabetic controls in a randomized, double blind, placebo-controlled trial to determine the effect of 15 weeks of treatment with metformin or placebo on glucose and lactate metabolism. Before and after treatment, all participants received a 7-h infusion of [6-3H]glucose and [3- 14C]lactate in combination with indirect calorimetry and estimation of lactate central vein specific activity. A euglycemic insulin clamp (20 mU/m2.min) was performed during the last 3 h of the tracer infusions. The study design allowed us to evaluate the effects of metformin vs. placebo treatment on glycemic control, plasma lipid profile, HGP, insulin-mediated glucose uptake, oxidative and nonoxidative glucose metabolism, and lactate turnover. Metformin treatment significantly reduced fasting plasma glucose (196 +/- 18 vs. 152 +/- 12 mg/dL; P < 0.01), hemoglobin A1 (12.5 +/- 0.6 vs. 9.2 +/- 0.3%; P < 0.01), and plasma triglyceride and low density lipoprotein cholesterol concentrations. When diabetics were compared to nondiabetic controls, basal HGP was higher (12.9 +/- 1.0 vs. 9.8 +/- 1.2 mumol/kg.min; P < 0.01) despite the presence of fasting hyperinsulinemia and insulin- mediated total body glucose disposal (10.9 +/- 0.9 vs. 20.2 +/- 3.3 mumol/kg.min; P < 0.01) was decreased. Metformin significantly reduced fasting HGP (from 12.9 +/- 0.7 to 11.0 +/- 0.5 mumol/kg.min; P < 0.01), but did not enhance total body glucose disposal during insulin stimulation (10.9 +/- 0.9 vs. 11.0 +/- 0.5 mumol/kg.min; P = NS). Neither oxidative nor nonoxidative glucose disposal was improved by metformin treatment. The fasting plasma lactate concentration (1.1 +/- 0.1 vs. 0.6 +/- 0.1 mmol/L) and lactate turnover (14.0 +/- 0.8 vs. 10.3 +/- 0.6 mumol/kg.min) were significantly increased in diabetics and strongly correlated (r = 0.68; P < 0.001). The percent gluconeogenesis derived from lactate was similar in diabetic and control subjects (17 +/- 2% vs. 15 +/- 2%; P = NS), but the estimated rate of gluconeogenesis from lactate was increased in the diabetic group (P < 0.01). Despite the significant reduction in HGP after metformin treatment, the percentage of gluconeogenesis from lactate and the rate of lactate-derived gluconeogenesis were unchanged from baseline. Basal lactate turnover (15.4 +/- 1.4 vs. 14.8 +/- 1.4 mumol/kg.min) and lactate oxidation (7.9 +/- 0.7 vs. 8.1 +/- 0.9 mumol/ kg.min) as well as total lactate turnover and lactate oxidation during the insulin clamp were similar before and after metformin treatment. There were no changes in any of the above metabolic parameters in the placebo-treated group. In poorly controlled NIDDM subjects, the primary mechanism by which metformin improves glycemic control is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis. Metformin has no effect on the rate of lactate turnover or gluconeogenesis from lactate in either the basal or insulin-stimulated states.

This article has been cited by other articles:

				L. Ibanez, A. Lopez-Bermejo, M. Diaz, M. V. Marcos, and F. de Zegher Metformin Treatment for Four Years to Reduce Total and Visceral Fat in Low Birth Weight Girls with Precocious Pubarche J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1841 - 1845. [Abstract] [Full Text] [PDF]

				J. M. Lachin, C. A. Christophi, S. L. Edelstein, D. A. Ehrmann, R. F. Hamman, S. E. Kahn, W. C. Knowler, D. M. Nathan, and on behalf of the DPP Research Group Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program Diabetes, April 1, 2007; 56(4): 1153 - 1159. [Abstract] [Full Text] [PDF]

				T. L. Skaer, D. A. Sclar, and L. M. Robison Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001: Does Type of Insurance Influence Access to Innovation? The Diabetes Educator, November 1, 2006; 32(6): 940 - 953. [Abstract] [Full Text] [PDF]

				C. R. Ong, L. M. Molyneaux, M. I. Constantino, S. M. Twigg, and D. K. Yue Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care, November 1, 2006; 29(11): 2361 - 2364. [Abstract] [Full Text] [PDF]

				S. Srinivasan, G. R. Ambler, L. A. Baur, S. P. Garnett, M. Tepsa, F. Yap, G. M. Ward, and C. T. Cowell Randomized, Controlled Trial of Metformin for Obesity and Insulin Resistance in Children and Adolescents: Improvement in Body Composition and Fasting Insulin J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2074 - 2080. [Abstract] [Full Text] [PDF]

				A. P. M. Viljanen, K. A. Virtanen, M. J. Jarvisalo, K. Hallsten, R. Parkkola, T. Ronnemaa, F. Lonnqvist, P. Iozzo, E. Ferrannini, and P. Nuutila Rosiglitazone Treatment Increases Subcutaneous Adipose Tissue Glucose Uptake in Parallel with Perfusion in Patients with Type 2 Diabetes: A Double-Blind, Randomized Study with Metformin J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6523 - 6528. [Abstract] [Full Text] [PDF]

				R. Belfort, L. Mandarino, S. Kashyap, K. Wirfel, T. Pratipanawatr, R. Berria, R. A. DeFronzo, and K. Cusi Dose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling Diabetes, June 1, 2005; 54(6): 1640 - 1648. [Abstract] [Full Text] [PDF]

				M. E. Cleasby, N. Dzamko, B. D. Hegarty, G. J. Cooney, E. W. Kraegen, and J.-M. Ye Metformin Prevents the Development of Acute Lipid-Induced Insulin Resistance in the Rat Through Altered Hepatic Signaling Mechanisms Diabetes, December 1, 2004; 53(12): 3258 - 3266. [Abstract] [Full Text] [PDF]

				J. B. Buse, R. R. Henry, J. Han, D. D. Kim, M. S. Fineman, A. D. Baron, and for the Exenatide-113 Clinical Study Group Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes Diabetes Care, November 1, 2004; 27(11): 2628 - 2635. [Abstract] [Full Text] [PDF]

				C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes Endocr. Rev., October 1, 2004; 25(5): 807 - 830. [Abstract] [Full Text] [PDF]

				A. Gastaldelli, Y. Miyazaki, M. Pettiti, E. Buzzigoli, S. Mahankali, E. Ferrannini, and R. A. DeFronzo Separate Contribution of Diabetes, Total Fat Mass, and Fat Topography to Glucose Production, Gluconeogenesis, and Glycogenolysis J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3914 - 3921. [Abstract] [Full Text] [PDF]

				M. Tiikkainen, A.-M. Hakkinen, E. Korsheninnikova, T. Nyman, S. Makimattila, and H. Yki-Jarvinen Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes Diabetes, August 1, 2004; 53(8): 2169 - 2176. [Abstract] [Full Text] [PDF]

				A. Natali, S. Baldeweg, E. Toschi, B. Capaldo, D. Barbaro, A. Gastaldelli, J. S. Yudkin, and E. Ferrannini Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1349 - 1357. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				P. Iozzo, K. Hallsten, V. Oikonen, K. A. Virtanen, R. Parkkola, J. Kemppainen, O. Solin, F. Lonnqvist, E. Ferrannini, J. Knuuti, et al. Effects of Metformin and Rosiglitazone Monotherapy on Insulin-Mediated Hepatic Glucose Uptake and Their Relation to Visceral Fat in Type 2 Diabetes Diabetes Care, July 1, 2003; 26(7): 2069 - 2074. [Abstract] [Full Text] [PDF]

				I. Pavo, G. Jermendy, T. T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B. J. Schluchter, et al. Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1637 - 1645. [Abstract] [Full Text] [PDF]

				The Diabetes Prevention Program Research Group Effects of Withdrawal From Metformin on the Development of Diabetes in the Diabetes Prevention Program Diabetes Care, April 1, 2003; 26(4): 977 - 980. [Abstract] [Full Text] [PDF]

				J. E. Gunton, P. J. D. Delhanty, S.-I. Takahashi, and R. C. Baxter Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2 J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1323 - 1332. [Abstract] [Full Text] [PDF]

				G C Jones, J P Macklin, and W D Alexander Contraindications to the use of metformin BMJ, January 4, 2003; 326(7379): 4 - 5. [Full Text] [PDF]

				M. Freemark Pharmacologic Approaches to the Prevention of Type 2 Diabetes in High Risk Pediatric Patients J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 3 - 13. [Full Text] [PDF]

				R. A Defronzo Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance? The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S24 - S40. [Abstract] [PDF]

				K. Hallsten, K. A. Virtanen, F. Lonnqvist, H. Sipila, A. Oksanen, T. Viljanen, T. Ronnemaa, J. Viikari, J. Knuuti, and P. Nuutila Rosiglitazone but Not Metformin Enhances Insulin- and Exercise-Stimulated Skeletal Muscle Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes Diabetes, December 1, 2002; 51(12): 3479 - 3485. [Abstract] [Full Text] [PDF]

				S. A. Hawley, A. E. Gadalla, G. S. Olsen, and D. G. Hardie The Antidiabetic Drug Metformin Activates the AMP-Activated Protein Kinase Cascade via an Adenine Nucleotide-Independent Mechanism Diabetes, August 1, 2002; 51(8): 2420 - 2425. [Abstract] [Full Text] [PDF]

				G. Mithieux, L. Guignot, J.-C. Bordet, and N. Wiernsperger Intrahepatic Mechanisms Underlying the Effect of Metformin in Decreasing Basal Glucose Production in Rats Fed a High-Fat Diet Diabetes, January 1, 2002; 51(1): 139 - 143. [Abstract] [Full Text] [PDF]

				B. R. Landau Methods for measuring glycogen cycling Am J Physiol Endocrinol Metab, September 1, 2001; 281(3): E413 - E419. [Abstract] [Full Text] [PDF]

				S. Song, S. Andrikopoulos, C. Filippis, A. W. Thorburn, D. Khan, and J. Proietto Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E275 - E282. [Abstract] [Full Text] [PDF]

				M. Freemark and D. Bursey The Effects of Metformin on Body Mass Index and Glucose Tolerance in Obese Adolescents With Fasting Hyperinsulinemia and a Family History of Type 2 Diabetes Pediatrics, April 1, 2001; 107(4): e55 - e55. [Abstract] [Full Text] [PDF]

				D. J. Jakubowicz, M. Seppälä, S. Jakubowicz, O. Rodriguez-Armas, A. Rivas-Santiago, H. Koistinen, R. Koistinen, and J. E. Nestler Insulin Reduction with Metformin Increases Luteal Phase Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein 1 Concentrations and Enhances Uterine Vascularity and Blood Flow in the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1126 - 1133. [Abstract] [Full Text]

				J. H. Scarpello Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2001; 1(1): 28 - 36. [Abstract] [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, H. K. Martikainen, and J. S. Tapanainen Endocrine and Metabolic Effects of Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3161 - 3168. [Abstract] [Full Text]

				V. Fonseca, J. Rosenstock, R. Patwardhan, and A. Salzman Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial JAMA, April 5, 2000; 283(13): 1695 - 1702. [Abstract] [Full Text] [PDF]

				A. Balasubramanyam, S. McKay, P. Nadkarni, A. S. Rajan, A. Garza, V. Pavlik, J. A. Herd, F. Jahoor, and P. J. Reeds Ethnicity affects the postprandial regulation of glycogenolysis Am J Physiol Endocrinol Metab, November 1, 1999; 277(5): E905 - E914. [Abstract] [Full Text] [PDF]

				R. A. DeFronzo Pharmacologic Therapy for Type 2 Diabetes Mellitus Ann Intern Med, August 17, 1999; 131(4): 281 - 303. [Abstract] [Full Text] [PDF]